OTHER ITEMS	9 Months Ended
Dec. 31, 2020
Other Income and Expenses [Abstract]
Other items	NOTE 7 – OTHER ITEMS (a) COVID-19 Pandemic The outbreak of COVID-19 originating in Wuhan, China, in December 2019 has since rapidly increased its exposure globally. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. We continue to monitor the global outbreak of COVID-19 and are working with our employees, suppliers and other stakeholders to mitigate the risks posed by its spread, COVID-19 is not expected to have any long-term detrimental effect on the Company’s success. While key suppliers have not been accessible throughout the whole period of the outbreak, we have been able to be flexible in our priorities and respond favorably to the challenges faced during the outbreak. We have also seen a surge in the uptake of technologies for remote and patient self-monitoring, which therefore potentially enhances the prospects for the likes of the Company and its CGM product and planned digital healthcare offering. (b) Management consultancy agreements During the nine month period ended December 31, 2020, $59,000 in stock-based compensation was shown as expense in relation to a management consulting company. No stock-based compensation was provided during the three month period ended December 31, 2020 for these services. Total stock-based compensation recognized during the three and nine month periods ended December 31, 2019 was $40,000 and $317,664, respectively. (c) Investor relations agreements During the three and nine month periods ended December 31, 2020, Nemaura entered into an agreement with a third party provider of investor relations services for which $25,000 in stock-based compensation was shown as expense in relation to the services received. The contract for services is for a 12 month period, with a similar expense expected to be incurred through stock-based compensation in each quarter of this term. No stock-based compensation expense was incurred for any similar services for the three or nine month periods ended December 31, 2019. (d) Subsequent events On February 8, 2021, the Company entered into an additional note purchase agreement (“Note Purchase Agreement 2”) with an affiliate of the unrelated third party who holds the existing Note Purchase Agreement that was issued dated April 15, 2020 (the “Investor”), see Note 6. Pursuant to the terms of Note Purchase Agreement 2, the Company agreed to issue and sell to the Investor and the Investor agreed to purchase from the Company, a secured promissory note (“Secured Note 2”) in the original principal amount of $24,015,000. In consideration thereof, on February 9, 2021 (the “closing date”), (i) the Investor paid $20,000,000 in cash to the Company, and (ii) the Company delivered Secured Note 2 on behalf of the Company, to the Investor, against the delivery of the Purchase Price. For these purposes, the “Purchase Price” means the Investor’s initial cash purchase price. After adjusting for commission expense of $1,200,000, cash proceeds received were $18,800,000. Secured Note 2 is secured against all of the Company’s assets owned as of the closing date and extends to any assets acquired at any time that the Company’s obligations under Secured Note 2 are outstanding. The Company has taken on this additional, non-dilutive funding, to enable the acceleration of future revenue growth.

OTHER ITEMS

9 Months Ended

Dec. 31, 2020

Other Income and Expenses [Abstract]

NOTE 7 – OTHER ITEMS

(a) COVID-19 Pandemic

The outbreak of COVID-19 originating in Wuhan, China, in December 2019 has since rapidly increased its exposure globally. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. We continue to monitor the global outbreak of COVID-19 and are working with our employees, suppliers and other stakeholders to mitigate the risks posed by its spread, COVID-19 is not expected to have any long-term detrimental effect on the Company’s success. While key suppliers have not been accessible throughout the whole period of the outbreak, we have been able to be flexible in our priorities and respond favorably to the challenges faced during the outbreak. We have also seen a surge in the uptake of technologies for remote and patient self-monitoring, which therefore potentially enhances the prospects for the likes of the Company and its CGM product and planned digital healthcare offering.

(b) Management consultancy agreements

During the nine month period ended December 31, 2020, $59,000 in stock-based compensation was shown as expense in relation to a management consulting company. No stock-based compensation was provided during the three month period ended December 31, 2020 for these services.

Total stock-based compensation recognized during the three and nine month periods ended December 31, 2019 was $40,000 and $317,664, respectively.

During the three and nine month periods ended December 31, 2020, Nemaura entered into an agreement with a third party provider of investor relations services for which $25,000 in stock-based compensation was shown as expense in relation to the services received. The contract for services is for a 12 month period, with a similar expense expected to be incurred through stock-based compensation in each quarter of this term.

No stock-based compensation expense was incurred for any similar services for the three or nine month periods ended December 31, 2019.

(d) Subsequent events

On February 8, 2021, the Company entered into an additional note purchase agreement (“Note Purchase Agreement 2”) with an affiliate of the unrelated third party who holds the existing Note Purchase Agreement that was issued dated April 15, 2020 (the “Investor”), see Note 6. Pursuant to the terms of Note Purchase Agreement 2, the Company agreed to issue and sell to the Investor and the Investor agreed to purchase from the Company, a secured promissory note (“Secured Note 2”) in the original principal amount of $24,015,000. In consideration thereof, on February 9, 2021 (the “closing date”), (i) the Investor paid $20,000,000 in cash to the Company, and (ii) the Company delivered Secured Note 2 on behalf of the Company, to the Investor, against the delivery of the Purchase Price. For these purposes, the “Purchase Price” means the Investor’s initial cash purchase price. After adjusting for commission expense of $1,200,000, cash proceeds received were $18,800,000.

Secured Note 2 is secured against all of the Company’s assets owned as of the closing date and extends to any assets acquired at any time that the Company’s obligations under Secured Note 2 are outstanding.

The Company has taken on this additional, non-dilutive funding, to enable the acceleration of future revenue growth.